Association between CD133 expression and clinicopathological profile in colorectal cancer

Yusuf F., Lindarto D., Putra A., Rey I.

Abstract

Aim To investigate CD133 expression and its relationship to clinicopathological profile in colorectal cancer (CRC) patients. Methods This cross-sectional study was performed at the Internal Medicine Department, School of Medicine, Adam Malik General Hospital. The colorectal cancer tissue was taken from surgical resection and colonoscopy biopsy from CRC patients. Clinical profile was obtained by a questionnaire. Histopathology examination was done using hematoxylin and eosin staining. Immunohistochemistry (distribution score and intensity score) combined with ROC analysis were conducted to determine CD133 expression. An association between CD133 expression and clinicopathological profile was then analyzed. Results Out of 118 patients, 690 (58.5%) were male. The high and low level of CD133 expression were found in 44 (37.3%) and 74 (62.7%) patients, respectively. No difference between gender, age, body mass index, hemoglobin, leucocytes, platelets, and histopathology with CD133 expression was found. There was a significant difference between CD133 and different CRC locations (p=0.002). CD133 expression was higher in the proximal colon than the rectum (p=0.002), and it was higher in the distal colon than the rectum (p=0.008), especially in terms of percentages of stained cancer cells (distribution score). Conclusion CD133 expression was associated with the tumour location, but not with other clinicopathological factors.

Journal
Medicinski Glasnik
Page Range
304-309
Publication date
2020
Total citations
Cited by 5
mTOR signal and hypoxia-inducible factor-1α regulate CD133 expression in cancer cells

Aomatsu K., Arao T., Fujita Y., Kaneda H., Kudo K., Matsumoto K., Nishio K., Saijo N., Tamura D., Tamura T., Tanaka K., Yamada Y.

A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2α

Acker T., Acker T., Acker T., Frisen J., Frisen J., Garvalov B.K., Henze A.-T., Lundeberg J., Meletis K., Nister M., Reifenberger G., Schanzer A., Seidel S., Sommerlad D., Von Stechow L., Wirta V., Wolter M.

Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α

Androutsellis-Theotokis A., Engh J., Iwama T., Kassam A.B., Kassam A.B., Kunisada T., Lee D., McKay R.D., Mintz A., Park D.M., Park D.M., Park M., Pollack I.F., Pollack I.F., Soeda A.

The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients

Aglietta M., Alabiso I., Alabiso O., Berruti A., Bitossi R., Brizzi M.P., Dogliotti L., Forti L., Gorzegno G., Harris A., Magnino A., Miraglia S., Saini A., Sculli C.M., Sperti E., Tampellini M.

CD133 Expression and the Prognosis of Colorectal Cancer: A Systematic Review and Meta-Analysis

Chen S., Chen Z., Li J., Li M., Li X., Liu H., Song X.

Does the prognosis of colorectal cancer vary with tumor site?

Fatemi S.R., Hajizadeh E., Jafarabadi M.A., Kazemnejad A., Mohammadi S.M.

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials

Aoyama T., Hamada C., Honda M., Kanda M., Kashiwabara K., Maeda H., Mayanagi S., Oba K., Sadahiro S., Saji S., Sakamoto J., Sakamoto J., Yoshikawa T.

CD133 marks for colorectal adenocarcinoma

Cheah P.-L., Chew M.-F., Teoh K.-H.

Immunohistochemical detection of CD133 expression in colorectal cancer: A clinicopathological study

Atsumi N., Fujii S., Ishii G., Kojima M., Ochiai A., Saito N.

CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies

Ai H., Huang R., Lu Y., Mo D., Wu J.

Access to Document

10.17392/1106-20